Novartis bullish about future despite Gleevec painThe patent loss of its biggest earning drug has hit Novartis’ revenues, which fell 1% in the third Share XNovartis bullish about future despite Gleevec painhttps://pharmaphorum.com/news/novartis-bullish-future-despite-gleevec-pain/
